Document is current
Any future updates will be listed below
-
Authors
Dai, Xiaoyun https://orcid.org/0000-0002-6162-5202
Park, Jonathan J. https://orcid.org/0000-0001-5887-3953
Du, Yaying https://orcid.org/0000-0002-3213-5722
Na, Zhenkun
Lam, Stanley Z.
Chow, Ryan D. https://orcid.org/0000-0002-1872-6307
Renauer, Paul A.
Gu, Jianlei
Xin, Shan https://orcid.org/0000-0002-4735-0935
Chu, Zhiyuan
Liao, Cun
Clark, Paul
Zhao, Hongyu https://orcid.org/0000-0003-1195-9607
Slavoff, Sarah https://orcid.org/0000-0002-4443-2070
Chen, Sidi https://orcid.org/0000-0002-3819-5005
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01GM122984, DP2CA238295, R01CA231112, R33CA225498, 1RF1DA048811, U54CA209992)
U.S. Department of Defense (W81XWH-21-1-0514)
- License Information
-
More Information
Article History
Received: 6 July 2022
Accepted: 12 December 2022
First Online: 26 January 2023
Competing interests
: A patent application has been filed by Yale University on CLASH (S.C., X.D., J.J.P. and Y.D. as inventors). S.C. is a founder of Cellinfinity Bio, which licensed the CLASH patent. S.C. is also a founder of EvolveImmune Tx, Chen Consulting and Chen Tech, unrelated to this study.
